Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Vincristine in Relapsed or Refractory ALL
NCT03504644Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Aug 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by ECOG-ACRIN Cancer Research Group. Started Aug 2018; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03504644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504644.